Torrent Pharmaceuticals' Q1 FY 2026-27 Quarterly Results
- 31 Jul 2026
Result Summary
- Torrent Pharmaceuticals Ltd reported a 17.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 56.3%.
- Its expenses for the quarter were up by 15.9% QoQ and 72.9% YoY.
- The net profit increased 55.5% QoQ and increased 3.3% YoY.
- The earnings per share (EPS) of Torrent Pharmaceuticals Ltd stood at 14.87 during Q1 FY 2026-27.
Financial Statments for Q1 FY 2026-27
(₹ crores) | Q1FY27 | Q4FY26 | Q1FY26 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 4909.00 | 4180.00 | 3141.00 | 17.4% | 56.3% |
Total Expenses | 4155.00 | 3585.00 | 2403.00 | 15.9% | 72.9% |
Profit Before Tax | 733.00 | 529.00 | 738.00 | 38.6% | -0.7% |
Tax | 167.00 | 165.00 | 190.00 | 1.2% | -12.1% |
Profit After Tax | 566.00 | 364.00 | 548.00 | 55.5% | 3.3% |
Earnings Per Share | 14.87 | 11.51 | 16.19 | 29.2% | -8.2% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Torrent Pharmaceuticals Ltd is a leading player in the pharmaceutical industry, primarily engaged in the manufacturing and marketing of branded and generic pharmaceutical products. The company operates across various therapeutic segments, including cardiovascular, central nervous system, gastrointestinal, and anti-infective, among others. As a major entity in the industry, Torrent Pharmaceuticals has established a strong presence in both domestic and international markets. Recent developments, such as product launches and strategic expansions, continue to shape its business landscape. However, the data does not provide specific recent developments for the company.
Revenue
In the first quarter of fiscal year 2027 (Q1FY27), Torrent Pharmaceuticals Ltd reported a total income of ₹4909.00 crores, marking a significant increase of 17.4% compared to the previous quarter (Q4FY26), where the total income was ₹4180.00 crores. Year-over-year (YoY), there is a substantial rise of 56.3% from ₹3141.00 crores in Q1FY26 to ₹4909.00 crores in Q1FY27. This growth demonstrates an upward trend in the company's revenue generation over the reported periods.
Profitability
Torrent Pharmaceuticals Ltd's profitability has seen notable changes over the reporting periods. In Q1FY27, the company achieved a profit before tax of ₹733.00 crores, which is a 38.6% increase from ₹529.00 crores in Q4FY26. However, when compared to Q1FY26, where the profit before tax was ₹738.00 crores, there is a slight decline of 0.7%. The profit after tax for Q1FY27 stands at ₹566.00 crores, showing a significant quarter-over-quarter increase of 55.5% from ₹364.00 crores in Q4FY26, and a 3.3% rise year-over-year from ₹548.00 crores in Q1FY26. Additionally, the earnings per share in Q1FY27 is ₹14.87, reflecting a 29.2% increase from Q4FY26 but an 8.2% decrease from ₹16.19 in Q1FY26.
Operating Metrics
Operating metrics for Torrent Pharmaceuticals Ltd highlight the company's expense management and tax obligations. Total expenses in Q1FY27 amounted to ₹4155.00 crores, a 15.9% increase from ₹3585.00 crores in the previous quarter. Year-over-year, expenses rose by 72.9% from ₹2403.00 crores in Q1FY26. The tax paid during Q1FY27 was ₹167.00 crores, showing a marginal increase of 1.2% from the previous quarter's ₹165.00 crores, and a decrease of 12.1% compared to ₹190.00 crores in Q1FY26. This data reflects the financial dynamics in the company's operating environment over the periods under review.
FAQs
Torrent Pharmaceuticals Ltd announced its Q1 FY 2026-27 results on 31 July, 2026.
Torrent Pharmaceuticals Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
Key highlights of Torrent Pharmaceuticals Ltd Q1 FY 2026-27 results include:
- Revenue: ₹4909.00 crore
- Net Profit: ₹566.00 crore
- EBITDA: ₹1631.00 crore
- Year-over-Year Growth: 56.3%
- Quarter-over-Quarter Growth: 17.4%
Torrent Pharmaceuticals Ltd reported a net profit of ₹566.00 crore in Q1 FY 2026-27, reflecting a 3.3% year-over-year growth.
Torrent Pharmaceuticals Ltd posted a revenue of ₹4909.00 crore in Q1 FY 2026-27.